Editorial: Immune Cell Lineage Reprogramming in Cancer

Jianmei W Leavenworth; Lewis Zhichang Shi; Xi Wang; Haiming Wei

doi:10.3389/fimmu.2021.838464

Editorial: Immune Cell Lineage Reprogramming in Cancer

Front Immunol. 2022 Jan 19:12:838464. doi: 10.3389/fimmu.2021.838464. eCollection 2021.

Authors

Jianmei W Leavenworth^{1

2

3}, Lewis Zhichang Shi^{2

3

4}, Xi Wang^{5

6

7

8}, Haiming Wei^{9

10}

Affiliations

¹ Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, United States.
² The O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States.
³ Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States.
⁴ Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States.
⁵ Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
⁶ Beijing Institute of Infectious Diseases, Beijing, China.
⁷ National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
⁸ Department of Oncology, Capital Medical University, Beijing, China.
⁹ Hefei National Laboratory for Physical Sciences at Microscale, Division of Life Science and Medicine, University of Science and Technology of China, Heifei, China.
¹⁰ Institute of Immunology, University of Science and Technology of China, Heifei, China.

No abstract available

Keywords: cancer immunotherapy; epigenetic regulation; helper T-cells; lineage reprogramming; natural killer cells; regulatory T-cells; tumor immunity; tumor-associated macrophages.

Publication types

Editorial
Introductory Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Adaptive Immunity
Animals
Cell Lineage* / genetics
Cell Lineage* / immunology
Cell Transformation, Neoplastic* / genetics
Cell Transformation, Neoplastic* / immunology
Cell Transformation, Neoplastic* / metabolism
Cellular Reprogramming* / genetics
Cellular Reprogramming* / immunology
Disease Management
Disease Susceptibility
Humans
Immune System*
Immunity, Innate
Neoplasms / etiology*
Neoplasms / metabolism*
Neoplasms / pathology
Neoplasms / therapy
Tumor Microenvironment

Publication types

MeSH terms

Grants and funding